Seer’s takeover contest escalated as its CEO, Omid Farokhzad, raised the company’s acquisition offer to $2.55 per share plus contingent value rights. The improved bid followed an earlier increase by Seer investors Bradley Radoff and Michael Torok to the same $2.55 terms, extending a dueling-bid dynamic. Seer’s board has rejected all offers to date, leaving the process open and increasing pressure on governance decisions as bids compete on structure and contingent value economics. The sequence of announcements has already driven significant price volatility, with Seer shares previously spiking on takeover headlines. The development matters for the diagnostics and proteomics sector because Seer’s potential transition to private control could affect timelines for product development, reimbursement strategy, and the pace of commercial expansion amid intensified competition for proteomics platforms.